Sonidegib for the Treatment of Advanced Basal Cell Carcinoma: A Comprehensive Review of Sonidegib and the Bolt Trial with 12-Month Update

References

• Madan V , LearJT, SzeimiesRM. Non-melanoma skin cancer. Lancet375(9715), 673–685 (2010).
   PubMed Web of Science ®Google Scholar
• Mohan SV , ChangAL. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Curr. Dermatol. Rep.3, 40–45 (2014).
   PubMedGoogle Scholar
• Chren MM , LinosE, TorresJS, StuartSE, ParvataneniR, BoscardinWJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J. Invest. Dermatol.133(5), 1188–1196 (2013).
   PubMed Web of Science ®Google Scholar
• Griffiths RW , SuvarnaSK, StoneJ. Do basal cell carcinomas recur after complete conventional surgical excision?Br. J. Plast. Surg.58(6), 795–805 (2005).
   PubMedGoogle Scholar
• Hill VK , GartnerJJ, SamuelsY, GoldsteinAM. The genetics of melanoma: recent advances. Annu. Rev. Genomics Hum. Genet.14, 257–279 (2013).
   PubMed Web of Science ®Google Scholar
• Goldstein AM , FraserMC, StruewingJPet al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N. Engl. J. Med.333(15), 970–974 (1995).
   PubMed Web of Science ®Google Scholar
• Goldstein AM , TuckerMA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch. Dermatol.137(11), 1493–1496 (2001).
   PubMedGoogle Scholar
• Mosterd K , KrekelsGA, NiemanFHet al. Surgical excision versus Mohs’ micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years’ follow-up. Lancet Oncol.9(12), 1149–1156 (2008).
   PubMed Web of Science ®Google Scholar
• Lo JS , SnowSN, ReiznerGT, MohsFE, LarsonPO, HruzaGJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J. Am. Acad. Dermatol.24(5 Pt 1), 715–719 (1991).
   PubMed Web of Science ®Google Scholar
• Seo SH , ShimWH, ShinDH, KimYS, SungHW. Pulmonary metastasis of basal cell carcinoma. Ann. Dermatol.23(2), 213–216 (2011).
   PubMed Web of Science ®Google Scholar
• Sekulic A , MangoldAR, NorthfeltDW, LorussoPM. Advanced basal cell carcinoma of the skin: targeting the Hedgehog pathway. Curr. Opin. Oncol.25(3), 218–223 (2013).
   PubMed Web of Science ®Google Scholar
• Epstein EH . Basal cell carcinomas: attack of the Hedgehog. Nat. Rev. Cancer8(10), 743–754 (2008).
   PubMed Web of Science ®Google Scholar
• Migden MR , GuminskiA, GutzmerRet al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind Phase 2 trial. Lancet Oncol.16(6), 716–728 (2015).
   PubMed Web of Science ®Google Scholar
• Nusslein-Volhard C , WieschausE. Mutations affecting segment number and polarity in Drosophila. Nature287(5785), 795–801 (1980).
   PubMed Web of Science ®Google Scholar
• Stone DM , HynesM, ArmaniniMet al. The tumour-suppressor gene patched encodes a candidate receptor for Sonic Hedgehog. Nature384(6605), 129–134 (1996).
   PubMed Web of Science ®Google Scholar
• Xie J , MuroneM, LuohSMet al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature391(6662), 90–92 (1998).
   PubMed Web of Science ®Google Scholar
• Aszterbaum M , RothmanA, JohnsonRLet al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol.110(6), 885–888 (1998).
   PubMed Web of Science ®Google Scholar
• Gailani MR , Stahle-BackdahlM, LeffellDJet al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet.14(1), 78–81 (1996).
   PubMed Web of Science ®Google Scholar
• Cooper MK , PorterJA, YoungKE, BeachyPA. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science280(5369), 1603–1607 (1998).
   PubMed Web of Science ®Google Scholar
• Keeler RF . Teratogenic compounds of Veratrum californicum (Durand) X. Cyclopia in rabbits produced by cyclopamine. Teratology3(2), 175–180 (1970).
   PubMedGoogle Scholar
• Incardona JP , GaffieldW, KapurRP, RoelinkH. The teratogenic Veratrum alkaloid cyclopamine inhibits Sonic Hedgehog signal transduction. Development125(18), 3553–3562 (1998).
   PubMed Web of Science ®Google Scholar
• Sanchez P , Ruiz I AltabaA. In vivo inhibition of endogenous brain tumors through systemic interference of Hedgehog signaling in mice. Mech. Dev.122(2), 223–230 (2005).
   PubMed Web of Science ®Google Scholar
• Dirix L , RuttenA. Vismodegib: a promising drug in the treatment of basal cell carcinomas. Future Oncol.8(8), 915–928 (2012).
   PubMed Web of Science ®Google Scholar
• Buonamici S , WilliamsJ, MorrisseyMet al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med.2(51), 51ra70 (2010).
   PubMed Web of Science ®Google Scholar
• Rodon J , TawbiHA, ThomasALet al. A Phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin. Cancer Res.20(7), 1900–1909 (2014).
   PubMed Web of Science ®Google Scholar
• Zollinger M , Lozac’hF, HurhE, EmotteC, BaulyH, SwartP. Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers. Cancer Chemother. Pharmacol.74(1), 63–75 (2014).
   PubMed Web of Science ®Google Scholar
• Skvara H , KalthoffF, MeingassnerJGet al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J. Invest. Dermatol.131(8), 1735–1744 (2011).
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals N . To evaluate the safety, local tolerability, PK and PD of LDE225 on sporadic superficial and nodular skin basal cell carcinomas (sBCC). www.clinicaltrials.gov/ct2/show/NCT01033019.
   Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Kumari A , ErmilovAN, AllenBL, BradleyRM, DlugoszAA, MistrettaCM. Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation. J. Neurophysiol.113(3), 1034–1040 (2015).
   PubMed Web of Science ®Google Scholar
• Dessinioti C , PlakaM, StratigosAJ. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Future Oncol.10(6), 927–936 (2014).
   PubMed Web of Science ®Google Scholar
• Standford University . An open-label pilot study to evaluate the efficacy and safety of a combination treatment of sonidegib and BKM120 for the treatment of advanced basal cell carcinomas. https://clinicaltrials.gov/ct2/show/NCT02303041.
   Google Scholar
• Sharpe HJ , PauG, DijkgraafGJet al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell27(3), 327–341 (2015).
   PubMed Web of Science ®Google Scholar
• Dummer R , GuminskiA, GutzmerRet al. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a Phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J. Am. Acad. Dermatol. doi: 10.1016/j.jaad.02.1226 (2016) ( Epub ahead of print).
   Google Scholar
• Basset-Seguin N , HauschildA, GrobJJet al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol.16(6), 729–736 (2015).
   PubMed Web of Science ®Google Scholar